Who are RAS 2410's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Krazati, Lumakras, MRTX849, AMG 510, ARCT-2303, RMC-6236.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ras-2410.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RAS 2410 — Competitive Intelligence Brief

RAS 2410 (RAS 2410) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RAS pathway inhibitor. Area: Oncology.

marketed RAS pathway inhibitor KRAS Oncology Small molecule Live · refreshed every 30 min

Target snapshot

RAS 2410 (RAS 2410) — Nan Chen,MD. RAS 2410 is a selective inhibitor of the RAS pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RAS 2410 TARGET	RAS 2410	Nan Chen,MD	marketed	RAS pathway inhibitor	KRAS
Krazati	ADAGRASIB	Bristol-Myers Squibb	marketed		GTPase KRas	2022-01-01
Lumakras	SOTORASIB	Amgen	marketed		GTPase KRas	2021-01-01
MRTX849	MRTX849	Mirati Therapeutics Inc.	phase 3	KRAS G12C inhibitor	KRAS G12C
AMG 510	AMG 510	Criterium, Inc.	phase 3	KRAS G12C inhibitor	KRAS G12C
ARCT-2303	ARCT-2303	Arcturus Therapeutics, Inc.	phase 3	Self-amplifying RNA (saRNA) vaccine	Tumor-associated antigens (KRAS, WT1, PRAME)
RMC-6236	RMC-6236	Revolution Medicines, Inc.	phase 3	KRAS G12C inhibitor	KRAS G12C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RAS pathway inhibitor class)

Nan Chen,MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RAS 2410 — Competitive Intelligence Brief. https://druglandscape.com/ci/ras-2410. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab